Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of Treating Cancer

a cancer and treatment method technology, applied in the field of cancer treatment, can solve the problems of abnormal deposition of unstructured bone, morbidity and mortality in crpc, modest improvement in survival, etc., and achieve the effect of prolonging the overall survival in patients

Inactive Publication Date: 2016-08-04
EXELIXIS INC
View PDF1 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025]In another aspect, the invention provides a method for treating or minimizing bone pain due to metastatic bone lesions associated with CRPC, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising Compound of Formula I or the malate salt of Compound of Formula I or another pharmaceutically acceptable salt of Compound of Formula I, to a patient in need of such treatment. In a specific embodiment, the Compound of Formula I is Compound 1.
[0029]In another aspect, the invention provides a method for extending the overall survival in patients with CRPC, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising Compound of Formula I or the malate salt of Compound of Formula I or another pharmaceutically acceptable salt of Compound of Formula I, to a patient in need of such treatment.

Problems solved by technology

Despite progress in systemic therapy for CRPC, improvements in survival are modest, and virtually all patients succumb to this disease within about 2 years.
The primary cause of morbidity and mortality in CRPC is metastasis to the bone, which occurs in about 90% of cases.
Although most CRPC patients with bone metastases display features of both types of lesions, prostate cancer bone metastases are often osteoblastic, with abnormal deposition of unstructured bone accompanied by increased skeletal fractures, spinal cord compression, and severe bone pain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of Treating Cancer
  • Method of Treating Cancer
  • Method of Treating Cancer

Examples

Experimental program
Comparison scheme
Effect test

embodiments

[0048]In one embodiment the compound of Formula I is the compound of Formula Ia:

or a pharmaceutically acceptable salt thereof, wherein:

[0049]R1 is halo;

[0050]R2 is halo; and

[0051]Q is CH or N.

[0052]In another embodiment, the compound of Formula I is Compound 1:

or a pharmaceutically acceptable salt thereof. As indicated previously, compound 1 is referred to herein as N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. WO 2005 / 030140 discloses Compound 1 and describes how it is made (Example 12, 37, 38, and 48) and also discloses the therapeutic activity of this compound to inhibit, regulate and / or modulate the signal transduction of kinases, (Assays, Table 4, entry 289). Example 48 is on paragraph [0353] in WO 2005 / 030140.

[0053]In other embodiments, the compound of Formula I, Ia, or Compound 1, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition, wherein the pharmaceutical composition addition...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
body weightaaaaaaaaaa
Login to View More

Abstract

This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of U.S. Ser. No. 13 / 876,290, filed Nov. 5, 2013, which claims priority under 35 U.S.C. §371 to Patent Cooperation Treaty application PCT / US2011 / 053233, filed Sep. 26, 2011, which claims the benefit of U.S. Provisional Application No. 61 / 481,671, filed May 2, 2011, and U.S. Provisional Application No. 61 / 386,959, filed Sep. 27, 2010, the entire contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.BACKGROUND OF THE INVENTION[0003]Castration-Resistant Prostate Cancer (CRPC) is a leading cause of cancer-related death in men. Despite progress in systemic therapy for CRPC, improvements in survival are modest, and virtually all patients succumb to this disease within about 2 years. The primary ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/47
CPCA61K31/00A61K31/47C07D215/22C07C55/02A61K31/517A61P13/08A61P19/00A61P35/00A61P35/04A61P43/00
Inventor SMITH, DAVID C.HUSSAIN, MAHA
Owner EXELIXIS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products